Civitas raises $38M to advance drug for Parkinson's complication

09/12/2013 | American City Business Journals

A Series B funding round has brought in $38 million for Chelsea, Mass.-based biotech firm Civitas Therapeutics. Civitas plans to use the money to support clinical development of its experimental drug CVT-301, which is under development for debilitating motor fluctuations in Parkinson's disease patients.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC